Post-Anoxic ComaNCT03308305
Cracking Coma: Towards EEG and MRI Based Precision Medicine After Cardiac Arrest
An observational study of Post-Anoxic Coma and Postanoxic Enchephalopathie, run by Rijnstate Hospital at 3 sites in Netherlands.
Trial summary
Rationale: 30-70% of comatose patients admitted to the intensive care unit (ICU) after cardiac arrest never regain consciousness as a result of post anoxic encephalopathy (PAE). Early identification of patients without potential for recovery of brain functioning may prevent inappropriate continuation of medical… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Post-Anoxic Coma, Postanoxic Enchephalopathie
- How many people
- 94 participants
- Where
- 3 sitesNetherlands
- Study dates
- 11 Jun 2018to 1 Nov 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population will consist of one hundred adult, comatose patients, successfully resuscitated from cardiac arrest. Generally, these patients are predominantly male and approximately 60-65 years of age. The patients are by definition at least temporarily incapacitated.
Who may be able to join
- Comatose, defined as Glasgow Coma Score ≤ 8
- Age ≥ 18 years
- Cardiac arrest with a presumed cardiac cause of the arrest or caused by pulmonary embolism
- Admission to ICU
Who cannot join
- Pregnancy
- Life expectancy < 24 hours
- Absence of written informed consent (by a legal representative)
- Pre-existing dependency in daily living, defined as CPC score 3 or 4
- Any known progressive brain illness, such as a brain tumor or neurodegenerative disease.
- Known contra-indication for MRI
Trial locations and contacts
3 sites in 1 country.
Netherlands3 sites
Rijnstate Hospital
Arnhem, Gelderland, 6815 AD
Maastricht University Medical Center
Maastricht
Radboud University Medical Centre
Nijmegen, Gelderland
About this study
Rationale: 30-70% of comatose patients admitted to the intensive care unit (ICU) after cardiac arrest never regain consciousness as a result of post anoxic encephalopathy (PAE). Early identification of patients without potential for recovery of brain functioning may prevent inappropriate continuation of medical treatment and improve communication between doctors and patients. However, current diagnostic and prognostic measures can identify only 20-50% of the patients with irreversible brain damage, precluding cerebral recovery and awakening. Also, the pathophysiology of brain damage is largely unclear. New magnetic resonance imaging (MRI) sequences hold potential to substantially improve outcome prediction.
Objectives: 1. To estimate the additional value of early MRI monitoring for the prediction of neurological outcome of comatose patients after cardiac arrest. 2. To gain insight in the pathophysiology of PAE by associating MRI findings with histopathological studies of brain tissue obtained from non-survivors.
Read more
Study design: prospective cohort study.
Study population: 100 subsequent comatose patients after cardiac arrest, admitted to the ICU.
Intervention: In addition to standard treatments, patients will undergo MRI of the brain at day 3, 7, and three months after cardiac arrest. A subgroup of patients will be scanned within 24 hours after cardiac arrest, to assess feasibility and to gain more insight in the evolution of brain damage in PAE. Survivors will be followed for one year. Outcome measurements will focus on disabilities, quality of life, and depression. MRI measures will be related to outcome.
Main study parameters/endpoints: The primary outcome measure is neurological outcome, defined as the score on the Cerebral Performance Category (CPC) at six months, dichotomized as good (CPC 1-2 = no or moderate neurological disability) or poor (CPC 3-5 = severe disability, coma, or death). Secondary outcome measures include cognitive functioning, depression, and quality of life at one year, as well as histopathological damage of brain tissue of non-survivors.
Read the detailed description
Standard procedures:
Patients will be monitored and treated according to guidelines for post out of hospital cardiac arrest treatment as described in local ICU protocols. Patients do not suffer any harm, disadvantage of discomfort while participating in this study.
Standard treatment includes targeted temperature management, hemodynamic monitoring and stabilisation, continuous EEG monitoring, blood sampling through the jugular bulb catheter, Near Infrared Spectroscopy (NIRS), and transcranial doppler (TCD) measurements. The patient's status is repeatedly assessed and treatment is based on the clinical findings.
Additional procedures:
- MRI A total of 3 MRI scans is planned for each patient: at day 3 ± 1, and day 7 ± 2 after cardiac arrest, and 3 months ± 2 weeks after cardiac arrest. The imaging protocol will consist of structural MRI (including FLAIR and ADC maps) to detect ischemic damage, a 3D T1 for structural analysis and SWI sequences to detect micro bleeds), structural connectivity measurement by DTI, and functional connectivity measurement by resting state BOLD functional MRI. Estimated time to prepare the patient and transport to and from the MRI scanner will be approximately 30 minutes, the scan itself will take approximately 30 minutes, as well. No intravenous contrast agent is used. 1.1 Acute phase MRI To estimate the feasibility of MRI scanning in the acute phase and to gain more insight in the dynamics of PAE, a subgroup of patients will be scanned within 24 hours after cardiac arrest. Patients will be included in this subgroup dependent on availability of the MRI facility, the clinical stability of the patients and after the patients legal representatives signed informed consent. 1.2 Transport to the radiology department The transport to and from the radiology department will be performed as described in the local protocols on patient transportation. Transport to and from other departments is a frequent procedure in ICU patients. During transport, the patient will be accompanied by a physician and ICU nurse. The MRI scans for this project will be handled as 'elective', which indicates that only patients with a stable hemodynamic and respiratory status will be transported to and undergo the MRI. For this, a patient has to meet all the following criteria:
- Hemodynamic stable condition, defined as:
- mean arterial pressure > 60 mmHg
- no or low inotropes or vasopressors (dosage norepinephrine < 0,3 ug/kg/min and/or dobutamine < 10 ug/kg/min or equivalent), dosage adjustments less than 0.1 ug/kg/min in the last hour before MRI
- Stable cardiac rhythm, defined as:
- sinus rhythm 50 - 120 beats per minute
- atrial fibrillation or flutter with ventricle response 60 - 120 per minute
- Pulmonary stable condition, defined as:
- Arterial oxygen saturation > 95%
- maximum fraction inspired oxygen < 60% with maximum level of positive end expiratory pressure of 10 cm H2O
- peak inspiratory pressure < 30 cmH2O or <5 l/min oxygen trough nasal cannula (for patients not on mechanical ventilation) Mechanical ventilation during transport and scanning will be provided by an MRI compatible ventilator. Extensive monitoring of vital functions will not be interrupted during transport or MRI scanning, by using a mobile trolley with MRI compatible monitoring and ventilation equipment. At all times, a physician and trained ICU nurse will accompany the patient. The medical team accompanying the patient can change treatment during transport and scanning to pursue optimal hemodynamics, pulmonary state, and/or comfort. 1.3 Clinical evaluation of MRI scans All structural MRI scans will be assessed by a radiologist and results are added to a patient's medical file. Patients and their families will be informed. However, MRI findings will not be taken into account for decisions on withdrawal of treatment. BOLD fMRI and DTI data will be analysed later.
- Outcome At 3 and 6 months, CPC score will be assessed by a telephone interview by a trained investigator. Additionally, at twelve months, for assessment of cognitive outcome, depression, quality of life, and care giver strain, the patient will be invited to the hospital or visited at his / her place of residence. If a patient dies during the follow-up, the cause of death will be requested from the general practitioner or medical specialist.
- Post mortem analysis From all patients that die in the hospital after PAE, permission to perform autopsy is sought for. Permission will be asked from the legal representative in the context of current care, after the patient has died. According to current care, brains will be removed and samples fixated within 24 hours at the local pathology departments. On samples from 8 brain areas (sensory- and motor cortex, thalamus, basal ganglia, upper brain stem) evaluation of the agonal state is performed on hematoxylin-eosin staining. Additionally, predefined sections, including all cortical layers and white matter, will be formalin fixed for further analyses.
- Conditions
- Post-Anoxic Coma, Postanoxic Enchephalopathie
- Keywords
- Coma, Cardiac arrest, Prognosis, MRI, EEG
- Medical subject headings
- Coma, Heart Arrest
What is being measured
The primary outcome is the main question the study is designed to answer.
Functional outcome
Functional outcome as defined on the Cerebral Performance Category , dichotomized as good (CPC 1-2 = no or moderate neurological disability) or poor (CPC 3-5 = severe disability, coma, or death)
Measured: 6 months after cardiac arrest
Secondary outcomes (6)
cognitive functioning as defined by professional Neuropsychological examination
By using a standardized Neuropsychological examination, the cognitive state of a patient will be assessed one year after the cardiac arrest. The examination will focus on memory, language, executive functioning, speed of information processing, concentration and attention and visuoconstruction.
Measured: 12 months after cardiac arrest
Presence of depression
Presence of depression is scored using a Dutch translation of the HADS questionnaire.
Measured: 12 months after cardiac arrest
histopathological damage of brain tissue of non-survivors
After fixation, histopathological staining will be performed on gray matter and white matter structures of the brain. Different stainings will be used to asses morphological damage, synaptic damage and membrane damage.
Measured: Autopsy will take place at the first workday after the patient died at the ICU after cardiac arrest. After 2 weeks, the brain will be cut and paraffine coupes will be made. Analyses of the coupes will take place in batches.
Early functional outcome
Functional outcome as defined on the Cerebral Performance Category, scored at discharge from the ICU and 3 months after cardiac arrest
Measured: At discharge from the ICU and 3 months after cardiac arrest.
Participation in society score
The USER-Participate questionnaire will be used to evaluate a subjects participation in society.
Measured: 12 months after cardiac arrest
EQ-5D-5L quality of life
Quality of life will be scored by the EQ-5D-5L questionnaire
Measured: 12 months after cardiac arrest
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Oct 2017
- Study start11 Jun 2018
- Primary completion1 Nov 2025
- Study completion1 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Post-Anoxic ComaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 94 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rijnstate Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- University Medical Center Nijmegen, Donders Centre for Cognitive Neuroimaging, Maastricht University Medical Center
- Responsible party
- Sponsor
- Investigators
- J Hofmeijer, PhD, Principal investigator, Rijnstate Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03308305
- Sponsor's protocol ID
- 2017-1006
- Status last verified
- Jan 2026
- First submitted
- 2 Oct 2017
- Last updated
- 30 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Verhulst MMLH, Keijzer HM, van Gils PCW, van Heugten CM, Meijer FJA, Tonino BAR, Bonnes JL, Delnoij TSR, Hofmeijer J, Helmich RC. Functional connectivity in resting-state networks relates to short-term global cognitive functioning in cardiac arrest survivors. Hum Brain Mapp. 2024 Oct 15;45(15):e26769. doi: 10.1002/hbm.26769.
PubMed 39449030Keijzer HM, Duering M, Pasternak O, Meijer FJA, Verhulst MMLH, Tonino BAR, Blans MJ, Hoedemaekers CWE, Klijn CJM, Hofmeijer J. Free water corrected diffusion tensor imaging discriminates between good and poor outcomes of comatose patients after cardiac arrest. Eur Radiol. 2023 Mar;33(3):2139-2148. doi: 10.1007/s00330-022-09245-w. Epub 2022 Nov 24.
PubMed 36418623Keijzer HM, Lange PAM, Meijer FJA, Tonino BAR, Blans MJ, Klijn CJM, Hoedemaekers CWE, Hofmeijer J, Helmich RC. MRI markers of brain network integrity relate to neurological outcome in postanoxic coma. Neuroimage Clin. 2022;36:103171. doi: 10.1016/j.nicl.2022.103171. Epub 2022 Aug 26.
PubMed 36058165Keijzer HM, Verhulst MMLH, Meijer FJA, Tonino BAR, Bosch FH, Klijn CJM, Hoedemaekers CWE, Hofmeijer J. Prognosis After Cardiac Arrest: The Additional Value of DWI and FLAIR to EEG. Neurocrit Care. 2022 Aug;37(1):302-313. doi: 10.1007/s12028-022-01498-z. Epub 2022 Apr 25.
PubMed 35469391
Study at a glance
From the registry record, last updated by the sponsor on 30 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cracking Coma: Towards EEG and MRI Based Precision Medicine After Cardiac Arrest
- ClinicalTrials.gov ID
- NCT03308305
- Acronym / sponsor ID
- 2017-1006
- Conditions
- Post-Anoxic Coma, Postanoxic Enchephalopathie
- Keywords
- Coma, Cardiac arrest, Prognosis, MRI, EEG
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 94 participants (actual)
- Lead sponsor
- Rijnstate HospitalUniversity, hospital or other
- Collaborators
- University Medical Center Nijmegen, Donders Centre for Cognitive Neuroimaging, Maastricht University Medical Center
- Study start
- 11 Jun 2018 (actual)
- Primary completion
- 1 Nov 2025 (actual)
- Study completion
- 1 Nov 2025 (actual)
- First posted
- 12 Oct 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rationale: 30-70% of comatose patients admitted to the intensive care unit (ICU) after cardiac arrest never regain consciousness as a result of post anoxic encephalopathy (PAE). Early identification of patients without potential for recovery of brain functioning may prevent inappropriate continuation of medical treatment and improve communication between doctors and patients. However, current diagnostic and prognostic measures can identify only 20-50% of the patients with irreversible brain damage, precluding cerebral recovery and awakening. Also, the pathophysiology of brain damage is largely unclear. New magnetic resonance imaging (MRI) sequences hold potential to substantially improve outcome prediction.
Objectives: 1. To estimate the additional value of early MRI monitoring for the prediction of neurological outcome of comatose patients after cardiac arrest. 2. To gain insight in the pathophysiology of PAE by associating MRI findings with histopathological studies of brain tissue obtained from non-survivors.
Study design: prospective cohort study.
Study population: 100 subsequent comatose patients after cardiac arrest, admitted to the ICU.
Intervention: In addition to standard treatments, patients will undergo MRI of the brain at day 3, 7, and three months after cardiac arrest. A subgroup of patients will be scanned within 24 hours after cardiac arrest, to assess feasibility and to gain more insight in the evolution of brain damage in PAE. Survivors will be followed for one year. Outcome measurements will focus on disabilities, quality of life, and depression. MRI measures will be related to outcome.
Main study parameters/endpoints: The primary outcome measure is neurological outcome, defined as the score on the Cerebral Performance Category (CPC) at six months, dichotomized as good (CPC 1-2 = no or moderate neurological disability) or poor (CPC 3-5 = severe disability, coma, or death). Secondary outcome measures include cognitive functioning, depression, and quality of life at one year, as well as histopathological damage of brain tissue of non-survivors.
Detailed description
Standard procedures:
Patients will be monitored and treated according to guidelines for post out of hospital cardiac arrest treatment as described in local ICU protocols. Patients do not suffer any harm, disadvantage of discomfort while participating in this study.
Standard treatment includes targeted temperature management, hemodynamic monitoring and stabilisation, continuous EEG monitoring, blood sampling through the jugular bulb catheter, Near Infrared Spectroscopy (NIRS), and transcranial doppler (TCD) measurements. The patient's status is repeatedly assessed and treatment is based on the clinical findings.
Additional procedures:
- MRI A total of 3 MRI scans is planned for each patient: at day 3 ± 1, and day 7 ± 2 after cardiac arrest, and 3 months ± 2 weeks after cardiac arrest. The imaging protocol will consist of structural MRI (including FLAIR and ADC maps) to detect ischemic damage, a 3D T1 for structural analysis and SWI sequences to detect micro bleeds), structural connectivity measurement by DTI, and functional connectivity measurement by resting state BOLD functional MRI. Estimated time to prepare the patient and transport to and from the MRI scanner will be approximately 30 minutes, the scan itself will take approximately 30 minutes, as well. No intravenous contrast agent is used. 1.1 Acute phase MRI To estimate the feasibility of MRI scanning in the acute phase and to gain more insight in the dynamics of PAE, a subgroup of patients will be scanned within 24 hours after cardiac arrest. Patients will be included in this subgroup dependent on availability of the MRI facility, the clinical stability of the patients and after the patients legal representatives signed informed consent. 1.2 Transport to the radiology department The transport to and from the radiology department will be performed as described in the local protocols on patient transportation. Transport to and from other departments is a frequent procedure in ICU patients. During transport, the patient will be accompanied by a physician and ICU nurse. The MRI scans for this project will be handled as 'elective', which indicates that only patients with a stable hemodynamic and respiratory status will be transported to and undergo the MRI. For this, a patient has to meet all the following criteria:
- Hemodynamic stable condition, defined as:
- mean arterial pressure > 60 mmHg
- no or low inotropes or vasopressors (dosage norepinephrine < 0,3 ug/kg/min and/or dobutamine < 10 ug/kg/min or equivalent), dosage adjustments less than 0.1 ug/kg/min in the last hour before MRI
- Stable cardiac rhythm, defined as:
- sinus rhythm 50 - 120 beats per minute
- atrial fibrillation or flutter with ventricle response 60 - 120 per minute
- Pulmonary stable condition, defined as:
- Arterial oxygen saturation > 95%
- maximum fraction inspired oxygen < 60% with maximum level of positive end expiratory pressure of 10 cm H2O
- peak inspiratory pressure < 30 cmH2O or <5 l/min oxygen trough nasal cannula (for patients not on mechanical ventilation) Mechanical ventilation during transport and scanning will be provided by an MRI compatible ventilator. Extensive monitoring of vital functions will not be interrupted during transport or MRI scanning, by using a mobile trolley with MRI compatible monitoring and ventilation equipment. At all times, a physician and trained ICU nurse will accompany the patient. The medical team accompanying the patient can change treatment during transport and scanning to pursue optimal hemodynamics, pulmonary state, and/or comfort. 1.3 Clinical evaluation of MRI scans All structural MRI scans will be assessed by a radiologist and results are added to a patient's medical file. Patients and their families will be informed. However, MRI findings will not be taken into account for decisions on withdrawal of treatment. BOLD fMRI and DTI data will be analysed later.
- Outcome At 3 and 6 months, CPC score will be assessed by a telephone interview by a trained investigator. Additionally, at twelve months, for assessment of cognitive outcome, depression, quality of life, and care giver strain, the patient will be invited to the hospital or visited at his / her place of residence. If a patient dies during the follow-up, the cause of death will be requested from the general practitioner or medical specialist.
- Post mortem analysis From all patients that die in the hospital after PAE, permission to perform autopsy is sought for. Permission will be asked from the legal representative in the context of current care, after the patient has died. According to current care, brains will be removed and samples fixated within 24 hours at the local pathology departments. On samples from 8 brain areas (sensory- and motor cortex, thalamus, basal ganglia, upper brain stem) evaluation of the agonal state is performed on hematoxylin-eosin staining. Additionally, predefined sections, including all cortical layers and white matter, will be formalin fixed for further analyses.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will consist of one hundred adult, comatose patients, successfully resuscitated from cardiac arrest. Generally, these patients are predominantly male and approximately 60-65 years of age. The patients are by definition at least temporarily incapacitated.
Key inclusion criteria (4 listed)
- Comatose, defined as Glasgow Coma Score ≤ 8
- Age ≥ 18 years
- Cardiac arrest with a presumed cardiac cause of the arrest or caused by pulmonary embolism
- Admission to ICU
Key exclusion criteria (6 listed)
- Pregnancy
- Life expectancy < 24 hours
- Absence of written informed consent (by a legal representative)
- Pre-existing dependency in daily living, defined as CPC score 3 or 4
- Any known progressive brain illness, such as a brain tumor or neurodegenerative disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Functional outcome
Time frame: 6 months after cardiac arrest
Functional outcome as defined on the Cerebral Performance Category , dichotomized as good (CPC 1-2 = no or moderate neurological disability) or poor (CPC 3-5 = severe disability, coma, or death)
6 secondary outcomes
cognitive functioning as defined by professional Neuropsychological examination
Time frame: 12 months after cardiac arrest
Presence of depression
Time frame: 12 months after cardiac arrest
histopathological damage of brain tissue of non-survivors
Time frame: Autopsy will take place at the first workday after the patient died at the ICU after cardiac arrest. After 2 weeks, the brain will be cut and paraffine coupes will be made. Analyses of the coupes will take place in batches.
Early functional outcome
Time frame: At discharge from the ICU and 3 months after cardiac arrest.
Participation in society score
Time frame: 12 months after cardiac arrest
EQ-5D-5L quality of life
Time frame: 12 months after cardiac arrest
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jan 2026.
- Results publication: PubMed 39449030Verhulst MMLH, Keijzer HM, van Gils PCW, van Heugten CM, Meijer FJA, Tonino BAR, Bonnes JL, Delnoij TSR, Hofmeijer J, Helmich RC. Functional connectivity in resting-state networks relates to short-term global cognitive functioning in cardiac arrest survivors. Hum Brain Mapp. 2024 Oct 15;45(15):e26769. doi: 10.1002/hbm.26769.
- Results publication: PubMed 36418623Keijzer HM, Duering M, Pasternak O, Meijer FJA, Verhulst MMLH, Tonino BAR, Blans MJ, Hoedemaekers CWE, Klijn CJM, Hofmeijer J. Free water corrected diffusion tensor imaging discriminates between good and poor outcomes of comatose patients after cardiac arrest. Eur Radiol. 2023 Mar;33(3):2139-2148. doi: 10.1007/s00330-022-09245-w. Epub 2022 Nov 24.
- Results publication: PubMed 36058165Keijzer HM, Lange PAM, Meijer FJA, Tonino BAR, Blans MJ, Klijn CJM, Hoedemaekers CWE, Hofmeijer J, Helmich RC. MRI markers of brain network integrity relate to neurological outcome in postanoxic coma. Neuroimage Clin. 2022;36:103171. doi: 10.1016/j.nicl.2022.103171. Epub 2022 Aug 26.
- Results publication: PubMed 35469391Keijzer HM, Verhulst MMLH, Meijer FJA, Tonino BAR, Bosch FH, Klijn CJM, Hoedemaekers CWE, Hofmeijer J. Prognosis After Cardiac Arrest: The Additional Value of DWI and FLAIR to EEG. Neurocrit Care. 2022 Aug;37(1):302-313. doi: 10.1007/s12028-022-01498-z. Epub 2022 Apr 25.
- Individual participant dataSharing planned: No
Related trials for Post-Anoxic Coma
RecruitingObservational study
Early WAKE-up Predictors After Out-of-Hospital Cardiac Arrest
Cardiac Arrest (CA), Anoxic Brain Injury
Not yet recruitingObservational study
QUality Of Life and surviVAl in carDIac arreSt Patients
Cardiac Arrest, Post-Anoxic Coma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
J Hofmeijer, PhD principal investigator
Rijnstate Hospital
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Post-Anoxic Coma and Postanoxic Enchephalopathie, run by Rijnstate Hospital at 3 sites in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Functional outcome (time frame: 6 months after cardiac arrest). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03308305, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2026.